-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, pharmaceutical companies have become the "sweet rice cakes" in the eyes of investors
.
According to incomplete statistics, the number of IPO pharmaceutical companies on the Science and Technology Innovation Board in the first half of the year has reached 23, with a total financing amount of over 18 billion yuan
.
Among them, many of these pharmaceutical companies have raised more than 1 billion yuan, including Aotai Biological, Zhijiang Biological, Baike Biological and so on
.
It is worth noting that the financing wave of the pharmaceutical industry continues in the second half of the year
.
Recently, a number of innovative pharmaceutical companies have completed financing one after another, most of which amounted to hundreds of millions of dollars
.
For example, on November 4, Changyu Pharmaceutical announced that it had completed a $40 million Series C financing and obtained over-raising
.
According to reports, the funds raised in this round of financing will continue to develop original dual-target molecules based on Changyu Pharmaceutical’s proprietary coupled drug technology platform, including the first product XG005, which will be launched in the United States and China, respectively, in phase III and phase II acute and chronic pain.
(Including tumor pain, bone and joint pain) clinical trials, phase II overseas clinical trials of transdermal product XG004, and the promotion of other pipeline products
.
At present, the current situation of pain treatment in China is far behind that of European and American countries, and it is limited to the difficulty of research and development.
For many years, no new drugs with good efficacy and high safety have been released.
Therefore, the domestic standard of living is improving day by day, and the original pain treatment methods can no longer satisfy the general public.
In the context of patients' pursuit of quality of life, the industry is very optimistic about the development prospects of Changyu Pharmaceutical's additional financing in this field
.
On November 1, the innovative R&D company Hodder Biosciences announced the completion of hundreds of millions of yuan in Series B financing.
This round of financing was led by Hillhouse Ventures, followed by Eli Lilly Asia Fund and old shareholder Yuansheng Ventures
.
It is reported that this round of financing will be used to support the clinical trials of the first product, expand the existing iPSC cell therapy product R&D pipeline, and develop the GMP automated closed production system
.
On the same day, Anjisheng Bio, which focuses on the research and development of innovative drugs for bone, joint and muscle diseases, also announced the completion of the B round of US$70 million in financing.
.
It is reported that this round of financing will be used to continue to promote the development of domestic and foreign clinical research trials of multiple drug candidates including AGA111, continue to expand the scale of the preclinical product pipeline, and further improve the creation of a management team with international experience and vision , To accelerate the industrialization of innovative drugs in the treatment of severe bone, joint and muscle diseases
.
From the perspective of the industry, behind the continuous entry of capital is a manifestation of the continuous rise of China's pharmaceutical innovation industry
.
In recent years, in the face of the growing domestic market, with the support of favorable policies and the increasing acceptance of innovative therapies in the country, local innovative companies are constantly developing innovative drugs, and are facing large-scale, Vietnamese While focusing on innovation in the domestic market, we are also constantly expanding the international market
.
In this context, of course, it will attract the attention of more and more strategic investors
.
On the whole, the industry predicts that in the future, the pharmaceutical industry will continue to obtain financing under the background of more and more favorable pharmaceutical policies.
This will also inject more momentum into the pharmaceutical market and better promote the pharmaceutical industry.
The industry continues to develop towards higher quality
.
.
According to incomplete statistics, the number of IPO pharmaceutical companies on the Science and Technology Innovation Board in the first half of the year has reached 23, with a total financing amount of over 18 billion yuan
.
Among them, many of these pharmaceutical companies have raised more than 1 billion yuan, including Aotai Biological, Zhijiang Biological, Baike Biological and so on
.
It is worth noting that the financing wave of the pharmaceutical industry continues in the second half of the year
.
Recently, a number of innovative pharmaceutical companies have completed financing one after another, most of which amounted to hundreds of millions of dollars
.
For example, on November 4, Changyu Pharmaceutical announced that it had completed a $40 million Series C financing and obtained over-raising
.
According to reports, the funds raised in this round of financing will continue to develop original dual-target molecules based on Changyu Pharmaceutical’s proprietary coupled drug technology platform, including the first product XG005, which will be launched in the United States and China, respectively, in phase III and phase II acute and chronic pain.
(Including tumor pain, bone and joint pain) clinical trials, phase II overseas clinical trials of transdermal product XG004, and the promotion of other pipeline products
.
At present, the current situation of pain treatment in China is far behind that of European and American countries, and it is limited to the difficulty of research and development.
For many years, no new drugs with good efficacy and high safety have been released.
Therefore, the domestic standard of living is improving day by day, and the original pain treatment methods can no longer satisfy the general public.
In the context of patients' pursuit of quality of life, the industry is very optimistic about the development prospects of Changyu Pharmaceutical's additional financing in this field
.
On November 1, the innovative R&D company Hodder Biosciences announced the completion of hundreds of millions of yuan in Series B financing.
This round of financing was led by Hillhouse Ventures, followed by Eli Lilly Asia Fund and old shareholder Yuansheng Ventures
.
It is reported that this round of financing will be used to support the clinical trials of the first product, expand the existing iPSC cell therapy product R&D pipeline, and develop the GMP automated closed production system
.
On the same day, Anjisheng Bio, which focuses on the research and development of innovative drugs for bone, joint and muscle diseases, also announced the completion of the B round of US$70 million in financing.
.
It is reported that this round of financing will be used to continue to promote the development of domestic and foreign clinical research trials of multiple drug candidates including AGA111, continue to expand the scale of the preclinical product pipeline, and further improve the creation of a management team with international experience and vision , To accelerate the industrialization of innovative drugs in the treatment of severe bone, joint and muscle diseases
.
From the perspective of the industry, behind the continuous entry of capital is a manifestation of the continuous rise of China's pharmaceutical innovation industry
.
In recent years, in the face of the growing domestic market, with the support of favorable policies and the increasing acceptance of innovative therapies in the country, local innovative companies are constantly developing innovative drugs, and are facing large-scale, Vietnamese While focusing on innovation in the domestic market, we are also constantly expanding the international market
.
In this context, of course, it will attract the attention of more and more strategic investors
.
On the whole, the industry predicts that in the future, the pharmaceutical industry will continue to obtain financing under the background of more and more favorable pharmaceutical policies.
This will also inject more momentum into the pharmaceutical market and better promote the pharmaceutical industry.
The industry continues to develop towards higher quality
.
